Bleeding events with dabigatran or warfarin in patients with venous thromboembolism

Thrombosis and Haemostasis

Volumn 115, Issue 2, 2016, Pages 291-298

  Majeed, Ammar ^a,b   Goldhaber, Samuel Z ^c   Kakkar, Ajay ^d   Kearon, Clive ^e   Eriksson, Henry ^f   Kreuzer, Jörg ^g   Feuring, Martin ^h   Hantel, Stephan ^g   Friedman, Jeffrey ^h   Schellong, Sebastian ⁱ   Schulman, Sam ^a,e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e MCMASTER UNIVERSITY   (Canada)

^f SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^g BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^h Friedman Consulting   (United States)

ⁱ ACADEMIC TEACHING HOSPITAL DRESDEN FRIEDRICHSTADT   (Germany)

Author keywords

Bleeding; Dabigatran; Venous thromboembolism; Vitamin K antagonists

Indexed keywords

DABIGATRAN; WARFARIN; ANTICOAGULANT AGENT; ANTITHROMBIN;

ADULT; AGED; ARTICLE; BLEEDING; CREATININE CLEARANCE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VENOUS THROMBOEMBOLISM; CHEMICALLY INDUCED; CONTROLLED STUDY; HEMORRHAGE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; RISK; TIME FACTOR;

AGED; ANTICOAGULANTS; ANTITHROMBINS; DABIGATRAN; DOUBLE-BLIND METHOD; FEMALE; HEMORRHAGE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; TIME FACTORS; VENOUS THROMBOEMBOLISM; WARFARIN;

EID: 84957111517     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH15-04-0319     Document Type: Article

References (17)

1. Deitelzweig SB, Johnson BH, Lin J, et al. Prevalence of clinical venous thromboembolism in the USA: current trends and future projections. Am J Hematol 2011; 86: 217–220.
2. Michota FA. Bridging the gap between evidence and practice in venous thromboembolism prophylaxis: the quality improvement process. J Gen Intern Med 2007; 22: 1762–1770.
3. Spencer FA, Emery C, Lessard D, et al. The Worcester Venous Thromboembolism study: a population-based study of the clinical epidemiology of venous thromboembolism. J Gen Intern Med 2006; 21: 722–727.
4. Schulman S, Kakkar AK, Goldhaber SZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764–772.
5. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–2352.
6. Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the S, et al. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 2005; 3: 692–694.
7. TIMI definitions for commonly used terms in clinical trials [Oct 1, 2014]. Available from: http://www.timi.org/wp-content/uploads/2010/10/TIMI-Defini tions.pdf. Accessed October 1, 2014.
8. Stangier J, Clemens A. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. Clin Appl Thromb Hemost 2009; 15 (Suppl 1): 9S-16S.
9. Limdi NA, Limdi MA, Cavallari L, et al. Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 2010; 56: 823–831.
10. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomised evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363–2372.
11. EMA. Pradaxa: EPAR–Product Information 2015 [2015–07–15]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000829/WC500041059.pdf.
12. Hokusai VTEI, Buller HR, Decousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–1415.
13. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.
14. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomised studies. Thromb J 2013; 11: 21.
15. Bauersachs R, Berkowitz SD, Brenner B, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–2510.
16. Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated with Dabigatran or Warfarin for Non-Valvular Atrial Fibrillation. Circulation 2014; Epub ahead of print.
17. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139–1151.